Mylan's EpiPen According to onefederal analysis, taxpayers may have overpaid for Mylan's EpiPen byas much as $1.27 billion over 10 years as a result of itsmisclassification. (Photo: Shutterstock)

Senators Ron Wyden, D-Oregon, and Chuck Grassley, R-Iowa, haveintroduced a bill that's aimed at the methods drug companies use toovercharge taxpayers for Medicaid rebates.

As The Hill reports, the bill, put forward by theincoming chairman and ranking member of the Senate FinanceCommittee, could mean that the two are looking for common ground ondrug prices.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Marlene Satter

Marlene Y. Satter has worked in and written about the financial industry for decades.